Matt is also excited about the recent launch of the Disability Diversity in Clinical Trials (DDiCT) initiative and how it will inform the development of medicines. This new initiative aligns with broader inclusion and diversity health equity commitments at Bristol Myers Squibb to address health disparities, clinical trial diversity, supplier diversity, employee giving, and workforce representation between 2020 and 2025. “This initiative is critical from a scientific standpoint, and I’m looking forward to the impact it will have on patients,” he said.
Feeling supported by the inclusive culture
In the big picture, Matt has found that the overall culture of inclusion in the workplace is a key part of creating an environment where everyone can be successful. From his manager and team to the larger company, he has had encouraging dialogues about the challenges encountered due to illness, and how to flex to work around them.
“Not all diagnoses are visible to others,” he said. “So it’s important to create a culture where we trust each other and have empathy and understanding for colleagues. Supporting mental and physical health of colleagues is so important, and flexibility in where and when to do work is a vital part of that. My team has been very flexible.”
Julie, too, has noticed the day-to-day flexibility that makes it possible to independently manage her work schedule with healthcare appointments and times when physical and cognitive issues arise. “Everyone here trusts each other,” she said. “We’re all in it together.”
Her current role is built on a culture of collaboration among colleagues. This supportive culture has helped to keep Bristol Myers Squibb at the forefront of scientific innovation that serves patients, through work in R&D and beyond.
“Working at BMS, I’m able to make meaningful contributions in the drug discovery process,” Julie said. “My hope is that, with the right medical treatment, patients can focus on enjoying their lives and doing the things they love with the people they love.”